IB. AMENDMENTS TO THE CLAIMS

Cancel claims 1-40 and 48-65 without prejudice to renewal.

Please enter the amendments to claims 41, 45, and 47, as shown below.

Please enter new claims 66-69, as shown below.

1.-40. (Canceled)

41. (Currently amended) A method for reducing the level of enzymatically active ~~inhibiting the activity of a~~ diacylglycerol O-acyltransferase (DGAT) ~~DGAT~~ protein in a mammalian host, said method comprising:

contacting a host cell that produces ~~said~~ DGAT protein with an agent that ~~inhibits the activity of said~~ reduces the level of enzymatically active DGAT protein.

42. (Original) The method according to Claim 41, wherein said agent is a small molecule.

43. (Original) The method according to Claim 42, wherein said agent is an antibody.

44. (Original) The method according to Claim 42, wherein said agent is a monoclonal antibody.

45. (Currently amended) A method of modulating a symptom in a mammalian host of a disease condition associated with diacylglycerol O-acyltransferase (DGAT) ~~DGAT~~ activity, said method comprising:

administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates said DGAT activity in said host.

46. (Original) The method according to Claim 45, wherein said symptom is hypertriglycemia.

47. (Currently amended) The method according to Claim 45, wherein said ~~syptom~~ symptom is obesity

48.-65. (Canceled)

66. (New) The method of claim 41, wherein the agent decreases expression of a gene encoding DGAT in the host.

67. (New) The method of claim 66, wherein the agent is an antisense molecule.

68. (New) The method of claim 41, wherein the DGAT protein is human DGAT protein.

69. (New) The method of claim 41, wherein the DGAT protein has at least about 90% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:06.